E-cigarette, or vaping, product use associated lung injury and the risks and benefits of a thorough infectious work-up

Respiratory Medicine Case Reports

Zachary Haynes¹  Tyler Church²  Andrew Mertz³  Sean McKay³  Shena Kravitz⁴  Jessica Lilley⁵ 

[1] Corresponding author.;Division of Internal Medicine, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA;Transitional Year Internship, Walter Reed National Military Medical Center, Bethesda, MD, USA;Uniformed Services University of the Health Sciences, Bethesda, MD, USA;

关键词: Tetrahydrocannabinol;    THC;    e-Cigarette, or vaping;    Product-use associated lung injury;    EVALI;    Vaping;   

DOI  :  

来源: DOAJ

【 摘 要 】

As of February 2020, over 2800 cases of lung injury associated with vapes have been reported in all 50 states (Cullen et al., 2019) [1]. This case is about a 29-year-old female with a five-year history of vaping tetrahydrocannabinol (THC) who presented with symptoms consistent with e-cigarette, or vaping, product-use associated lung injury (EVALI). This case report is unique because this patient clinically improved on a lower dose of corticosteroids compared to other reported cases of EVALI. Additionally, this case report highlights the importance and difficulty of excluding other disease processes prior to treating patients for EVALI, particularly during the coronavirus disease 2019 (COVID-19) global pandemic.

【 授权许可】

Unknown